Dirk Brockstedt
Chief Tech/Sci/R&D Officer chez RAPT THERAPEUTICS, INC.
Fortune : 249 824 $ au 31/03/2024
Profil
Dirk G.
Brockstedt is currently the Chief Scientific Officer at Rapt Therapeutics, Inc. and an Executive-in-Residence at ShangPharma Innovation, Inc. Previously, he held positions as the Immunology Director at Cerus Corp.
from 2002 to 2007, Director-Research at Anza Therapeutics, Inc. from 2007 to 2009, and Senior Research Scientist at Aventis, Inc. He also served as the Executive Vice President-Research & Development at Aduro BioTech, Inc. from 2016 to 2017.
Dr. Brockstedt obtained his graduate and doctorate degrees from the University of Kiel.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
RAPT THERAPEUTICS, INC.
0,08% | 31/01/2024 | 27 820 ( 0,08% ) | 249 824 $ | 31/03/2024 |
Postes actifs de Dirk Brockstedt
| Sociétés | Poste | Début |
|---|---|---|
| RAPT THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/06/2019 |
ShangPharma Innovation, Inc.
 ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | Consultant / Advisor | - |
Anciens postes connus de Dirk Brockstedt
| Sociétés | Poste | Fin |
|---|---|---|
| CHINOOK THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/12/2017 |
Anza Therapeutics, Inc.
 Anza Therapeutics, Inc. Medical SpecialtiesHealth Technology Anza Therapeutics, Inc. develops products in the fields of cancer and infectious diseases. It also develops immunotherapy for infectious diseases, therapeutic vaccines for treating cancers that over-express Mesothelin and for treating people infected with the hepatitis C virus (HCV). The company was founded in 2007 and is headquartered in Concord, CA. | Chief Tech/Sci/R&D Officer | 01/01/2009 |
| CERUS CORPORATION | Corporate Officer/Principal | 01/01/2007 |
| Aventis, Inc. | Corporate Officer/Principal | - |
Formation de Dirk Brockstedt
| University of Kiel | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| CERUS CORPORATION | Health Technology |
| RAPT THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
| Aventis, Inc. | |
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
Anza Therapeutics, Inc.
Anza Therapeutics, Inc. Medical SpecialtiesHealth Technology Anza Therapeutics, Inc. develops products in the fields of cancer and infectious diseases. It also develops immunotherapy for infectious diseases, therapeutic vaccines for treating cancers that over-express Mesothelin and for treating people infected with the hepatitis C virus (HCV). The company was founded in 2007 and is headquartered in Concord, CA. | Health Technology |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | Finance |
